Skip to main content
Book cover

Penile Cancer pp 93–109Cite as

Multimodal Approach to Locally Advanced and Metastatic Penile Cancer

  • 731 Accesses

Part of the Current Clinical Urology book series (CCU)

Abstract

Squamous cell carcinoma of the penis is a rare cancer, with inguinal lymph node metastasis being the most important prognostic factor for the disease. Loco-regionally advanced disease has traditionally been managed by surgery and postoperative radiotherapy, but a multimodal approach to treatment has evolved over the past 20 years. The latest evidence suggests that neoadjuvant platinum-based triplet systemic chemotherapy can provide good outcomes for men with bulky or initially unresectable nodal metastases, with response rates as high as 65 %, enabling consolidation surgery in a fair proportion of men and achieving pathologic complete responses in 10–16 %. Nevertheless, survival outcomes for men with locally advanced or metastatic disease are moderate, with a 5-year overall survival of 50 % being the best outlook for men who respond to neoadjuvant chemotherapy, which represents an improvement on historical survival rates. The past few years have seen greater emphasis on determining the effect of human papillomavirus infection in penile cancer and outlining prognostic cohorts, together with investigation of targeted therapy, mainly for metastatic disease. It is hoped that multi-institutional collaboration within the International Rare Cancers Initiative will provide the first randomized data on men with locally advanced or metastatic disease, and outline novel treatment paradigms of how the integration of systemic chemotherapy, radiotherapy, surgery, and targeted therapy can be effectively used in a multimodal manner.

Keywords

  • Penile cancer
  • Multimodal therapy
  • Neoadjuvant
  • Chemotherapy
  • Radiotherapy
  • Surgery
  • Targeted therapy
  • International Rare Cancers Initiative

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4939-6679-0_8
  • Chapter length: 17 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   84.99
Price excludes VAT (USA)
  • ISBN: 978-1-4939-6679-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   109.99
Price excludes VAT (USA)
Hardcover Book
USD   109.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 8.1
Fig. 8.2
Fig. 8.3
Fig. 8.4

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    CrossRef  PubMed  Google Scholar 

  2. Goodman MT, Hernandez BY, Shvetsov YB. Demographic and pathologic differences in the incidence of invasive penile cancer in the United States, 1995–2003. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1833–9. [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.].

    Google Scholar 

  3. Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993;72(5 Pt 2):817–9.

    CAS  CrossRef  PubMed  Google Scholar 

  4. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52. [Clinical Trial Comparative Study Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.].

    Google Scholar 

  5. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21. [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural].

    Google Scholar 

  6. Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2000;48(4):1007–13. [Clinical Trial Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.].

    Google Scholar 

  7. Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol. 2007;52(2):488–94.

    CAS  CrossRef  PubMed  Google Scholar 

  8. Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006;98(6):1225–7.

    CAS  CrossRef  PubMed  Google Scholar 

  9. Pond GR, Milowsky MI, Kolinsky MP, Eigl BJ, Necchi A, Harshman LC, et al. Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. Clin Genitourin Cancer. 2014;12(6):440–6.

    CrossRef  PubMed  Google Scholar 

  10. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851–7. [Clinical Trial, Phase II Research Support, N.I.H., Extramural].

    Google Scholar 

  11. Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008;19(7):1304–7. [Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Extramural].

    Google Scholar 

  12. Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer. 2015;13(1):44–9.

    CrossRef  PubMed  Google Scholar 

  13. Hakenberg OW, Wirth MP. Issues in the treatment of penile carcinoma. A short review. Urol Int. 1999;62(4):229–33. [Review].

    Google Scholar 

  14. Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol. 1997;32(1):5–15. [Research Support, Non-U.S. Gov’t Review].

    Google Scholar 

  15. Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol. 2008;54(1):161–8.

    CrossRef  PubMed  Google Scholar 

  16. Ficarra V, Akduman B, Bouchot O, Palou J, Tobias-Machado M. Prognostic factors in penile cancer. Urology. 2010;76(2 Suppl 1):S66–73. [Review].

    Google Scholar 

  17. Slaton JW, Morgenstern N, Levy DA, Santos Jr MW, Tamboli P, Ro JY, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165(4):1138–42.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823–4. [Research Support, Non-U.S. Gov’t].

    Google Scholar 

  19. Nicolai N, Sangalli LM, Necchi A, Giannatempo P, Paganoni AM, Colecchia M, et al. A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings. Clin Genitourin Cancer. 2016;14(4):323–30.

    CrossRef  PubMed  Google Scholar 

  20. Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann. 2012;4(3):150–3.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  21. Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol. 2015;33(11):496.e17–23.

    Google Scholar 

  22. Hakenberg OW, Comperat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67(1):142–50. [Practice Guideline].

    Google Scholar 

  23. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, et al. Penile cancer: clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2013;11(5):594–615. [Practice Guideline].

    Google Scholar 

  24. Burt LM, Shrieve DC, Tward JD. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys. 2014;88(1):94–100.

    CrossRef  PubMed  Google Scholar 

  25. Chen MF, Chen WC, Wu CT, Chuang CK, Ng KF, Chang JT. Contemporary management of penile cancer including surgery and adjuvant radiotherapy: an experience in Taiwan. World J Urol. 2004;22(1):60–6.

    CrossRef  PubMed  Google Scholar 

  26. Franks KN, Kancherla K, Sethugavalar B, Whelan P, Eardley I, Kiltie AE. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol. 2011;186(2):524–9. [Research Support, Non-U.S. Gov’t].

    Google Scholar 

  27. Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol. 2006;93(2):133–8.

    CrossRef  PubMed  Google Scholar 

  28. Novara G, Galfano A, De Marco V, Artibani W, Ficarra V. Prognostic factors in squamous cell carcinoma of the penis. Nat Clin Pract Urol. 2007;4(3):140–6. [Review].

    Google Scholar 

  29. Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999;161(6):1823–5. [Clinical Trial Research Support, U.S. Gov’t, P.H.S.].

    Google Scholar 

  30. Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol. 2002;167(4):1638–42. [Comparative Study].

    Google Scholar 

  31. Dickstein RJ, Munsell MF, Pagliaro LC, Pettaway CA. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int. 2016;117(1):118–25.

    CAS  CrossRef  PubMed  Google Scholar 

  32. Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109(10):2554–9. [Clinical Trial, Phase II Multicenter Study Research Support, Non-U.S. Gov’t].

    Google Scholar 

  33. Longpre MJ, Lange PH, Kwon JS, Black PC. Penile carcinoma: lessons learned from vulvar carcinoma. J Urol. 2013;189(1):17–24. [Comparative Study Review].

    Google Scholar 

  34. Ravi R, Chaturvedi HK, Sastry DV. Role of radiation therapy in the treatment of carcinoma of the penis. Br J Urol. 1994;74(5):646–51.

    CAS  CrossRef  PubMed  Google Scholar 

  35. Chhabra A, Schwartz D, Leaf A, Karanikolas N, Weiss JP, Schreiber D. Neoadjuvant concurrent chemoradiation for curative treatment of penile squamous cell carcinoma. Case Rep Oncol Med. 2014;2014:479376.

    PubMed  PubMed Central  Google Scholar 

  36. Eliason M, Bowen G, Bowen A, Hazard L, Samlowski W. Primary treatment of verrucous carcinoma of the penis with fluorouracil, cis-diamino-dichloro-platinum, and radiation therapy. Arch Dermatol. 2009;145(8):950–2. [Case Reports Letter].

    Google Scholar 

  37. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20(4):449–57. [Research Support, Non-U.S. Gov’t Review].

    Google Scholar 

  38. Flaherty A, Kim T, Giuliano A, Magliocco A, Hakky TS, Pagliaro LC, et al. Implications for human papillomavirus in penile cancer. Urol Oncol. 2014;32(1):53.e1–8. [Review].

    Google Scholar 

  39. Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer. 2001;91(12):2315–21. [Research Support, Non-U.S. Gov’t].

    Google Scholar 

  40. Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer. 2006;119(5):1078–81.

    CAS  CrossRef  PubMed  Google Scholar 

  41. Chaux A, Munari E, Katz B, Sharma R, Lecksell K, Cubilla AL, et al. The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. Hum Pathol. 2013;44(12):2690–5. [Research Support, Non-U.S. Gov’t].

    Google Scholar 

  42. Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011;29(22):e650–2. [Case Reports].

    Google Scholar 

  43. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014;83(1):159–65. [Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].

    Google Scholar 

  44. Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014;113(6):871–7. [Research Support, N.I.H., Extramural].

    Google Scholar 

  45. Zhu Y, Li H, Yao XD, Zhang SL, Zhang HL, Shi GH, et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int. 2010;85(3):334–40.

    CrossRef  PubMed  Google Scholar 

  46. Keat N, Law K, Seymour M, Welch J, Trimble T, Lascombe D, et al. International rare cancers initiative. Lancet Oncol. 2013;14(2):109–10.

    CrossRef  PubMed  Google Scholar 

  47. Nicholson S, Kayes O, Minhas S. Clinical trial strategy for penis cancer. BJU Int. 2014;113(6):852–3.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA

    Praful Ravi M.B. Bchir.

  2. Department of Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA

    Lance C. Pagliaro M.D.

Authors
  1. Praful Ravi M.B. Bchir.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lance C. Pagliaro M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lance C. Pagliaro M.D. .

Editor information

Editors and Affiliations

  1. Department of Genitourinary Oncology, Department of Tumor Biology, Moffitt Cancer Center, Tampa, Florida, USA

    Philippe E. Spiess

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Ravi, P., Pagliaro, L.C. (2017). Multimodal Approach to Locally Advanced and Metastatic Penile Cancer. In: Spiess, P. (eds) Penile Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6679-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6679-0_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6677-6

  • Online ISBN: 978-1-4939-6679-0

  • eBook Packages: MedicineMedicine (R0)